Business
REX Retail Offer
REX Retail Offer.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\n \nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE REX RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF FUSION ANTIBODIES PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF FUSION ANTIBODIES PLC.\n \n19 May 2023\n \nFusion Antibodies plc\n(\"Fusion\" or the \"Company\")\n \nREX Retail Offer\n \nFusion Antibodies plc (AIM: FAB) is pleased to announce a retail offer via REX (the \"REX Retail Offer\") of ordinary shares (\"Ordinary Shares\") of 4 pence each in the capital of the Company (the \"REX Retail Offer Shares\")\n \nIn addition to the REX Retail Offer, the Company has conducted a placing of 28,431,746 new Ordinary Shares (the \"Placing Shares\") to raise £1.42 million (the \"Placing\") and a subscription for 2,740,000 new Ordinary Shares (the \"Subscription Shares\") by certain directors and their families to raise an additional £137,000 (the \"Subscription\"). The Placing has been conducted in two tranches, as follows:\n \n· 2,601,494 Placing Shares will be issued and allotted utilising the Company's existing shareholder authorities to issue new Ordinary Shares on a non-pre-emptive basis granted at the Company's most recent annual general meeting (the \"First Placing\"); and \n· 25,830,252 Placing Shares will be ...